Vitestro Secures $70 Million Series B to Advance Autonomous Robotic Phlebotomy

Dutch medical robotics company Vitestro has successfully closed an oversubscribed Series B financing round, raising $70 million to accelerate the development and commercialization of its Aletta® Autonomous Robotic Phlebotomy Device™ (ARPD™). The funding will be used to refine the robotics platform for automated blood collection, prepare for market launch, and expand clinical studies.

Revolutionizing Blood Collection with Robotics and AI

Vitestro, based in Utrecht, is pioneering a system designed to automate the entire diagnostic blood collection process. The Aletta® ARPD™ combines robotics, multimodal imaging, and artificial intelligence to identify suitable veins, precisely guide needle insertion, and collect blood samples with high accuracy and consistency. Vitestro aims to improve the efficiency, standardization, and patient experience of a procedure performed billions of times annually worldwide.

A Broad Investor Consortium Backs Vitestro’s Vision

The Series B round attracted a diverse group of strategic investors and institutional capital providers, including:

• Labcorp Venture Fund
• Mayo Clinic
• Sutter Health
• InterVest
• MGFO
• PGGM
• Puma Venture Capital
• ROM Utrecht
• Invest-NL
• EIC Fund
• Fred Moll
• NYBC Ventures
• Sonder Capital

Addressing Healthcare Staffing Challenges

According to Toon Overbeeke, CEO and co-founder of Vitestro, the oversubscribed funding round demonstrates strong investor confidence in the company’s vision. Vitestro has transitioned from an innovative concept to a clinically validated solution. The autonomous platform is intended to alleviate the burden on medical staff by automating routine blood collections, allowing healthcare professionals to focus on more complex patient care tasks. Standardized procedures and improved precision are also expected to enhance quality and efficiency in diagnostic centers.

Preparing for FDA Approval and Global Expansion

A portion of the funding will be dedicated to preparing for the FDA approval process through the de novo pathway in the United States. Vitestro is also focused on scaling production, conducting further clinical studies, and establishing an international sales infrastructure. Vitestro released its first public video in January 2026 demonstrating the Aletta® ARPD™ performing a diagnostic blood draw.

Industry Veteran Fred Moll Joins as Supporter

Vitestro has also gained the support of robotics pioneer Fred Moll, co-founder of Intuitive Surgical and Auris Health. Moll believes Vitestro is addressing a significant opportunity to modernize one of the largest and least-automated clinical processes. Med-Tech World highlights Aletta™ as the first autonomous phlebotomy device.

Vitestro plans to use the new capital to accelerate platform development, launch pilot programs with hospitals, and gradually roll out its technology worldwide, aiming to establish automated blood collection as a standard component of modern diagnostic workflows.